Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Dynamic contrast-enhanced MRI of malignant pleural mesothelioma : a comparative study of pharmacokinetic models and correlation with mRECIST criteria
Avtorji:ID Vivoda Tomšič, Martina, Klinika Golnik, Zdravstvena fakulteta UL (Avtor)
ID Bisdas, Sotirios (Avtor)
ID Kovač, Viljem (Avtor)
ID Serša, Igor (Avtor)
ID Šurlan Popović, Katarina (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (3,44 MB)
MD5: 41B4E44FD68C3B54D40C4E419AE7E246
 
URL URL - Izvorni URL, za dostop obiščite https://cancerimagingjournal.biomedcentral.com/articles/10.1186/s40644-019-0189-5
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic malignancy that is difficult to cure. Dynamic contrast-enhanced (DCE) MRI is a functional imaging technique used to analyze tumor microvascular properties and to monitor therapy response. Purpose of this study was to compare two tracer kinetic models, the extended Tofts (ET) and the adiabatic approximation tissue homogeneity model (AATH) for analysis of DCE-MRI and examine the value of the DCE parameters to predict response to chemotherapy in patients with MPM. METHOD: This prospective, longitudinal, single tertiary radiology center study was conducted between October 2013 and July 2015. Patient underwent DCE-MRI studies at three time points: prior to therapy, during and after cisplatin-based chemotherapy. The images were analyzed using ET and AATH models. In short-term follow-up, the patients were classified as having disease control or progressive disease according to modified response evaluation criteria in solid tumors (mRECIST) criteria. Receiver operating characteristic curve analysis was used to examine specificity and sensitivity of DCE parameters for predicting response to therapy. Comparison tests were used to analyze whether derived parameters are interchangeable between the two models. RESULTS: Nineteen patients form the study population. The results indicate that the derived parameters are not interchangeable between the models. Significant correlation with response to therapy was found for AATH-calculated median pre-treatment efflux rate (kep) showing sensitivity of 83% and specificity of 100% (AUC 0.9). ET-calculated maximal pre-treatment kep showed 100% sensitivity and specificity for predicting treatment response during the early phase of the therapy and reached a favorable trend to significant prognostic value post-therapy. CONCLUSION: Both models show potential in predicting response to therapy in MPM. High pre-treatment kep values suggest MPM disease control post-chemotherapy.
Ključne besede:biomarker, magnetic resonance imaging, mesothelioma, perfusion, response evaluation criteria in solid tumors, prognosis
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Velika Britanija
Založnik:Springer Nature
Leto izida:2019
Št. strani:str. [1-11]
Številčenje:Vol. 19, no. 10
PID:20.500.12556/DiRROS-12433 Novo okno
UDK:616-07
ISSN pri članku:1470-7330
DOI:10.1186/s40644-019-0189-5 Novo okno
COBISS.SI-ID:3175035 Novo okno
Avtorske pravice:© The Author(s). 2019
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 8. 3. 2019;
Datum objave v DiRROS:23.09.2020
Število ogledov:1294
Število prenosov:950
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Cancer imaging
Založnik:e-MED
ISSN:1470-7330
COBISS.SI-ID:523568409 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:16.01.2019

Nazaj